论文部分内容阅读
目的 观察以羟基喜树碱 (HPT)为主的HEP和HTP方案治疗晚期非小细胞肺癌的疗效及其毒副反应。方法 2 2例晚期非小细胞肺癌患者分别应用HEP方案 (VM -2 610 0mg ,d1-5;静脉滴注 :HPT 10mg ,d1-5,静脉滴注 :PDD 2 0mg ,d1-5,静脉滴注 )或HEP方案 (VP 1610 0mg ,d1-5:静脉滴注 :HPT 10mg ,d1-5,静脉滴注 :PDD 2 0mg ,d1-5,静脉滴注 )联合化疗 ,4周重复 ,2周期后按WHO标准进行评价。结果 2 2例患者中CR 1例 ,PR 8例 ,总有效率 40 .9% ;主要毒副反应为骨髓抑制和消化道反应。结论 以羟基喜树碱为主的HEP和HTP方案治疗晚期非小细胞肺癌的疗效较高 ,毒副反应可以耐受 ,值得临床进一步观察。
Objective To observe the curative effect and toxicity of HCP and HTP with hydroxycamptothecin (HPT) on advanced non-small cell lung cancer. Methods Twenty-two patients with advanced non-small cell lung cancer were treated with HEP regimen (VM-610 0 mg, d1-5; intravenous drip: HPT 10 mg, d1-5, intravenous drip: PDD 20 mg, d1-5, Note) or HEP regimen (VP 1610 0mg, d1-5: Intravenous drip: HPT 10mg, d1-5, Intravenous drip: PDD 20mg, d1-5, Intravenous drip) After evaluation by WHO standards. Results Among the 2 2 patients, CR was 1 and PR was 8, with a total effective rate of 40.9%. The main toxicities were myelosuppression and digestive tract reaction. Conclusions Hydroxycamptothecinate-based HEP and HTP regimens are effective in treating advanced non-small cell lung cancer and their toxicity is tolerable. It is worth further clinical observation.